novel
coronaviru
infect
known
coronaviru
diseas
becom
endem
emerg
situat
world
health
organ
far
success
specif
treatment
found
diseas
report
nonsurvivor
patient
septic
shock
significantli
higher
surviv
one
although
exact
pathophysiolog
septic
shock
patient
still
unclear
seem
possibl
part
would
due
administr
empir
antibiot
inflammatori
properti
especi
absenc
bacteri
infect
herein
review
possibl
molecular
pathway
septic
shock
patient
receiv
antibiot
inflammatori
properti
mainli
releas
interleukin
tumor
necrosi
factor
tnfa
differ
rout
altogeth
highli
recommend
clinician
look
antibiot
antiinflammatori
activ
empir
antibiot
therapi
reduc
inflamm
prevent
septic
shock
patient
diagnos
imss
publish
elsevi
inc
pathophysiolog
approach
key
regul
sepsi
especi
septic
shock
activ
nuclear
factorkappa
b
nfkb
turn
trigger
overexpress
differ
proinflammatori
cytokin
interleukin
tumor
necrosi
factor
tnfa
previous
highlight
consumpt
antibiot
lack
bacteri
infect
could
lead
inflammatori
storm
direct
indirect
pathway
direct
pathway
antibiot
stimul
immun
cell
secret
proinflammatori
cytokin
tnfa
figur
exampl
shown
singl
dose
ceftazidim
induc
express
tnfa
absenc
infect
asid
proinflammatori
cytokin
antibiot
could
also
increas
express
differ
tolllik
receptor
tlr
especi
indirect
pathway
studi
shown
treatment
antibiot
absenc
bacteri
infect
could
caus
increas
gut
endotoxin
neomycin
sulfat
streptomycin
even
result
endotoxemia
tobramycin
plu
polymyxin
ciprofloxacin
accord
figur
overexpress
well
lipopolysaccharid
releas
endotoxemia
could
lead
overexpress
proinflammatori
cytokin
activ
nfkb
treatment
cours
patient
diagnos
antibiot
therapi
one
backbon
treatment
patient
receiv
accord
data
enough
evid
virusinduc
sepsi
septic
shock
patient
regard
mention
effect
antibiot
administr
nonbacteri
infecti
situat
author
suggest
administr
antibiot
patient
proceed
care
prevent
antibioticinduc
inflammatori
storm
also
clinician
may
look
antibiot
antiinflammatori
activ
empir
antibiot
therapi
reduc
inflamm
reduc
septic
shock
